400
Participants
Start Date
March 31, 2022
Primary Completion Date
April 16, 2024
Study Completion Date
November 28, 2025
Brigimadlin
Brigimadlin taken orally on day 1 of each 21-day cycle (q3w).
Doxorubicin
Intravenous infusion of 75 milligram per square meter (mg/m2) on Day 1 of each 21-day cycle (q3w) until a maximum cumulative dose of 450 mg/m2 (approximately 6 cycles).
National Taiwan University Hospital, Taipei
Prince of Wales Hospital-Randwick-66496, Randwick
Herlev and Gentofte Hospital, Herlev
Peter MacCallum Cancer Centre, Melbourne
UZ Leuven, Leuven
Princess Alexandra Hospital, Woolloongabba
Ashford Cancer Centre Research, Kurralta Park
AOU San Luigi Gonzaga, Orbassano (TO)
Istituto Di Candiolo, Candiolo (TO)
Taipei Veterans General Hospital, Taipei
"Attikon University General Hospital of Attica", Haidari
Helios Klinikum Berlin-Buch, Berlin
HOP Timone, Marseille
Helios Klinikum Bad Saarow, Bad Saarow
Hospital Clínico de Santiago, Santiago de Compostela
Karolinska Universitetssjukhuset Stockholm, Stockholm
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Skånes universitetssjukhus, Lund
Asklepios Kliniken GmbH & Co. KGaA, Hamburg
Humanitas Gavazzeni, Bergamo
Hospital General Universitario Gregorio Marañón, Madrid
Fundación Jiménez Díaz, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario HM Sanchinarro, Madrid
Hospital Virgen de la Victoria, Málaga
Winship Cancer Institute, Atlanta
Medizinische Hochschule Hannover, Hanover
INS Claudius Regaud IUCT-Oncopole, Toulouse
Mayo Clinic Cancer Center, Jacksonville
INS Bergonie, Bordeaux
Tampere University Hospital, Tampere
CTR Eugène Marquis, Rennes
Istituto Oncologico Veneto IRCCS, Padua
University of Alabama at Birmingham, Birmingham
Henry-Joyce Cancer Clinic, Nashville
University Hospitals of Cleveland, Cleveland
Universitätsklinikum Essen AöR, Essen
University of Michigan Health System, Ann Arbor
Hospital Miguel Servet, Zaragoza
Froedtert and The Medical College of Wisconsin, Milwaukee
Bioclinic Thessaloniki, Thessaloniki
Mayo Clinic, Rochester, Rochester
CTR Oscar Lambret, Lille
Barnes-Jewish Hospital, St Louis
Masaryk Memorial Cancer Institute, Brno
Nebraska Cancer Specialists-Omaha-69502, Omaha
Universitätsklinikum Mannheim GmbH, Mannheim
CTR Leon Berard, Lyon
Robert Bosch Gesellschaft für medizinische Forschung mbH, Stuttgart
HOP Cochin, Paris
University of Texas Southwestern Medical Center, Dallas
University Hospital Olomouc, Olomouc
Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli
Klinikum der Universität München AÖR, München
Huntsman Cancer Institute, Salt Lake City
University of Arizona, Tucson
University of Southern California, Los Angeles
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo
Precision NextGen Oncology, Beverly Hills
Sarcoma Oncology Center, Santa Monica
City of Hope-Duarte-56419, Duarte
INS Gustave Roussy, Villejuif
Oregon Health and Sciences University, Portland
Cancer Hospital of Chinese Academy of Medical Science, Beijing
Beijing Cancer Hospital, Beijing
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Zhongshan Hospital Affiliated to Fudan University, Shanghai
Zhejiang Cancer Hospital, Hangzhou
Wuhan Union Hospital, Wuhan
Sun Yat-Sen University Cancer Center, Guangzhou
West China Hospital of Sichuan University, Chengdu
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
BC Cancer Agency - Vancouver, Vancouver
The Ottawa Hospital, Ottawa
Princess Margaret Cancer Centre, Toronto
Maisonneuve-Rosemont Hospital, Montreal
Motol University Hospital, Prague
HUCH Comprehensive Cancer Center, building 2, Helsinki
Technische Universität Dresden, Dresden
Hippokration General Hospital of Athen, Athens
Prince of Wales Hospital-Hong Kong-20715, Hong Kong
Università Campus Bio-Medico - ROMA, Roma
Aichi Cancer Center Hospital, Aichi, Nagoya
Nagoya University Hospital, Aichi, Nagoya
National Cancer Center Hospital East, Chiba, Kashiwa
National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka
Kyushu University Hospital, Fukuoka, Fukuoka
Tohoku University Hospital, Miyagi, Sendai
Okayama University Hospital, Okayama, Okayama
Osaka International Cancer Institute, Osaka, Osaka
Hokkaido Cancer Center, Sapporo, Hokkaido
National Cancer Center Hospital, Tokyo, Chuo-ku
Japanese Foundation for Cancer Research, Tokyo, Koto-ku
Nederlands Kanker Instituut, Amsterdam
Leids Universitair Medisch Centrum (LUMC), Leiden
Oslo Universitetssykehus HF, Radiumhospitalet, Oslo
IPO Lisboa Francisco Gentil, EPE, Lisbon
ULS de Santa Maria, E.P.E, Lisbon
Hospital Santa Creu i Sant Pau, Barcelona
Hospital Universitari Vall D Hebron, Barcelona
Hospital Duran i Reynals, L'Hospitalet de Llobregat
Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara
Addenbrooke's Hospital, Cambridge
Velindre Cancer Centre, Cardiff
Churchill Hospital, Headington
University College Hospital, London
The Royal Marsden Hospital, Chelsea, London
Lead Sponsor
Boehringer Ingelheim
INDUSTRY